INTRODUCTION
RA is a common disease (prevalence 0.5-1%),' with a tendency for ongoing inflammation, which may lead to progressive joint destruction, functional impairment and handicap. Spontaneous remissions are rare and it is now known that significant joint damage can occur within the first two years of disease onset.2'3 Modern management strategies stress the importance of early diagnosis and treatment with disease modifying anti-rheumatic drugs (DMARDs), particularly methotrexate, which is now the "gold standard" by which other therapies are judged. 4 Despite this, a significant number of patients ( alone (8%), compared with those receiving methotrexate with infliximab (6%).8 A major trial comparing etanercept alone with methotrexate alone in early RA found no difference in the rate of serious infections between the groups (both less than 3%).9 The slightly lower serious infection rate in this study may be partly attributable to the fact that these patients had early, rather than established, rheumatoid disease. The BSR is compiling a registry on the use of anti-TNF drugs with control groups not receiving either drug, which should allow a more formal assessment ofthe relative risk ofinfectious disease attributable to anti-TNF therapy in clinical practice.1' In our study the average age of patients who developed serious infection was greater than in the cohort as a whole (65 versus 51 years) and this has led to even greater caution in the use of these drugs in older patients, particularly those with multiple co-morbidities. 19 Combinations of biological agents which work at different points in the inflammatory cascade may ultimately make the induction ofdisease remission a realistic prospect.
In conclusion, our experience in Northern Ireland over a two year period has confirmed that the anti-TNF therapies, etanercept and infliximab, represent a significant advance in the treatment of severe RA and JIA. They are also of benefit in other inflammatory arthritides such as psoriatic arthritis and ankylosing spondylitis. Adverse events in this cohort were not uncommon, and there were a number of serious infections in our patients (5%). These sometimes occurred rapidly and with little warning. We therefore recommend that these drugs be administered only in specialist centres to carefully selected patients. Our experience confirms the need for careful ongoing safety monitoring of these patients.
